Dermatological Drugs Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented by Dermatological Diseases (Acne, Dermatitis, Psoriasis, Skin Cancer, Others), By Route of Administration (Oral, Parenteral, Topical), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), by region, and Competition
Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationDermatological Drugs Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented by Dermatological Diseases (Acne, Dermatitis, Psoriasis, Skin Cancer, Others), By Route of Administration (Oral, Parenteral, Topical), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), by region, and Competition
| Forecast Period | 2024-2028 |
| Market Size (2022) | USD18.20 billion |
| CAGR (2023-2028) | 9.10 % |
| Fastest Growing Segment | Alopecia Segment |
| Largest Market | North America |
Market Overview
Global Dermatological Drugs Market has valued at USD 18.20 billion in 2022 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 9.10% through 2028.
The high prevalence of various skin conditions, including acne, psoriasis, eczema, skin cancer, and dermatitis, drives the demand for dermatological drugs. Skin conditions affect a significant portion of the global population, leading to a consistent market demand.
Key Market Drivers
Rising Aging Population
As people age, their skin undergoes natural changes, becoming thinner, less elastic, and more susceptible to damage. This makes the elderly population more prone to various dermatological conditions, including skin cancer, eczema, psoriasis, and age-related skin disorders. Skin cancer risk increases with age, and older individuals are more likely to develop skin cancers such as basal cell carcinoma, squamous cell carcinoma, and melanoma. This drives the demand for dermatological drugs used in the prevention, treatment, and management of skin cancer. Many dermatological conditions are chronic and may worsen with age. Conditions like psoriasis, rosacea, and seborrheic dermatitis often require ongoing treatment, leading to sustained demand for dermatological drugs. Aging is associated with cosmetic concerns such as wrinkles, fine lines, and age spots. The desire to maintain a youthful appearance drives demand for dermatological drugs, including topical treatments, dermal fillers, and botulinum toxin injections.
Chronic itching, a common problem in older adults, can result from various skin conditions or systemic diseases. Dermatological drugs that relieve itching are often prescribed to improve the quality of life for elderly patients. Actinic keratosis, a precancerous skin condition caused by sun exposure, is more common in older individuals. Treating this condition often involves the use of topical dermatological drugs. Older adults are more likely to be taking multiple medications for various health conditions. Some medications can have dermatological side effects, necessitating additional dermatological drug treatments. Older individuals tend to have more frequent healthcare visits, including visits to dermatologists. This increased interaction with healthcare providers results in a higher likelihood of dermatological drug prescriptions. The economic impact of an aging population is substantial, as older adults often have more disposable income to spend on healthcare, including dermatological treatments. The pharmaceutical industry recognizes the growing market potential of dermatological drugs for the aging population. Consequently, there is a focus on developing innovative treatments to address age-related skin conditions. Older individuals are increasingly seeking cosmetic procedures, such as chemical peels and laser therapy, to address age-related skin concerns. These procedures often complement dermatological drug treatments. This factor will help in the development of the
Advancements in Dermatological Research
Dermatological research has led to the development of biologic drugs and targeted therapies that specifically address the underlying causes of skin conditions. For example, biologics like TNF-alpha inhibitors and IL-17 inhibitors have revolutionized the treatment of conditions like psoriasis. Advances in genomics and genetics have deepened our understanding of the genetic basis of many skin disorders. Researchers have identified specific genetic mutations associated with conditions like epidermolysis bullosa and ichthyosis, leading to potential gene therapies and precision medicine approaches. Research into skin cancer has led to improved early detection methods, such as dermoscopy and confocal microscopy. Additionally, targeted therapies and immunotherapies have emerged as effective treatments for melanoma and other skin cancers. Research on wound healing and tissue regeneration has resulted in the development of advanced wound dressings, tissue-engineered skin substitutes, and regenerative therapies for conditions like chronic ulcers and burns.
Dermatological research has contributed to the development of cosmetic treatments, including injectables (e.g., dermal fillers and botulinum toxin), laser therapy, and chemical peels, to address aesthetic concerns like wrinkles, fine lines, and pigmentation issues. Ongoing research has led to the development of improved topical treatments and oral medications for various skin conditions, such as acne, eczema, and psoriasis. These treatments offer better efficacy and safety profiles. Advances in immunology and dermatology have led to a better understanding of autoimmune skin diseases like lupus and dermatomyositis. This knowledge has paved the way for targeted immunosuppressive therapies. Research into telemedicine and digital health solutions has expanded access to dermatological care. Teledermatology has enabled remote consultations, diagnosis, and treatment planning, especially in underserved areas. Understanding the skin barrier function and its role in dermatological conditions has led to the development of barrier repair creams and emollients for conditions like atopic dermatitis. Research into the skin microbiome has revealed its importance in maintaining skin health and preventing conditions like acne and dermatitis. This knowledge may lead to microbiome-based therapies in the future. Nanotechnology research has led to the development of nano-formulations for dermatological drug delivery, enhancing the penetration and efficacy of topical treatments. This factor will pace up the demand of the
Increased Focus on Aesthetics
Aesthetic dermatology, also known as cosmetic dermatology, encompasses a wide range of procedures and products aimed at enhancing the appearance of the skin and addressing various aesthetic concerns.
Dermatological drugs and procedures like CoolSculpting and Kybella are used for non-surgical body contouring to reduce localized fat deposits, such as double chins. Dermatological drugs like minoxidil and finasteride are used to address hair loss and promote hair regrowth. Hair restoration procedures, including platelet-rich plasma (PRP) therapy, are also popular in aesthetic dermatology. For individuals with scars from surgery, injuries, or burns, dermatological treatments such as laser therapy, corticosteroid injections, and silicone gel sheets can help improve the appearance of scars. The use of injectables like dermal fillers and neurotoxins for facial enhancement is widespread in aesthetic dermatology. These products are often administered by dermatologists to address volume loss and facial lines. Dermatological drugs and chemical peels are used to exfoliate the skin, improve texture, and address issues like acne, sun damage, and pigmentation irregularities. Increasingly, individuals are seeking aesthetic treatments to boost their confidence and enhance their appearance. This patient demand drives the growth of the aesthetic dermatology market. Advances in dermatological technology have made aesthetic procedures safer, more effective, and less invasive, contributing to their popularity. The use of cosmeceuticals, which are a combination of cosmetics and pharmaceuticals, has grown. These products often contain active ingredients aimed at improving skin health and appearance. This factor will accelerate the demand of the Global Dermatological Drugs Market.
Key Market Challenges
Resistance and Tolerance
Resistance to topical antibiotics can develop in the treatment of conditions like acne and impetigo. Prolonged use of antibiotics may lead to the development of antibiotic-resistant strains of bacteria on the skin. Resistance to antifungal drugs can occur in the treatment of fungal skin infections, such as dermatophytosis (ringworm) and candidiasis. Fungi can develop resistance to commonly used antifungal agents. Prolonged use of topical corticosteroids can lead to skin thinning and tolerance, where the drug becomes less effective in managing inflammatory skin conditions like eczema and psoriasis. In some cases, acne-causing bacteria can become resistant to antibiotics commonly used in acne treatment. This has led to the development of alternative treatments and the importance of antibiotic stewardship. Some individuals may develop tolerance to OTC products like benzoyl peroxide or salicylic acid when used for acne for acne. This may necessitate a change in treatment or the addition of other therapies. In conditions like psoriasis, the immune system can become resistant to certain treatments, such as topical corticosteroids or phototherapy. This may require the use of different classes of drugs or combination therapies.
Market Competition
Numerous pharmaceutical companies, ranging from large multinational corporations to smaller niche players, compete in the dermatological drugs market. This intense competition can make it challenging for companies to gain market share and maintain pricing power. Competition often leads to price pressure, especially for generic dermatological drugs. As multiple manufacturers produce similar generic products, pricing becomes highly competitive, which can impact profit margins. Some segments of the dermatological drugs market, such as acne treatments and corticosteroid creams, may become saturated with multiple products that offer similar benefits. This saturation makes it challenging for companies to differentiate their offerings and capture market share. Developing innovative dermatological drugs that stand out in the market requires significant research and development investment. Companies must continually innovate to differentiate their products and gain a competitive edge. The regulatory approval process for dermatological drugs can be time-consuming and expensive. Meeting regulatory standards and obtaining approvals for new drugs or formulations is a considerable challenge. The expiration of patents on dermatological drugs can open the door to generic competition, resulting in a loss of market exclusivity and reduced revenue for brand-name drug manufacturers. In some regions, counterfeit or substandard dermatological drugs may enter the market, posing risks to patient safety and eroding trust in the industry. Expanding into new geographic markets requires navigating varying regulatory environments, adapting to local preferences, and competing with established players in those regions.
Key Market Trends
Personalized Medicine
Individuals can respond differently to dermatological treatments due to genetic variations. Personalized medicine seeks to identify these genetic factors to predict treatment responses and outcomes accurately. Pharmacogenomics is the study of how an individual's genetic makeup influences their response to medications. In dermatology, this is particularly relevant for drugs used to treat conditions like psoriasis and acne. Personalized medicine is crucial in the treatment of skin cancers, such as melanoma. Genetic profiling of tumors can guide treatment decisions, including the use of targeted therapies and immunotherapies. Genetic factors play a role in atopic dermatitis (eczema). Personalized medicine can help identify specific genetic markers that influence disease severity and treatment response, allowing for tailored interventions. Genetic testing and molecular diagnostics can help dermatologists select the most appropriate treatment for specific skin conditions, ensuring better outcomes and minimizing side effects. Some companies have developed customized topical treatments based on individual skin characteristics and needs. These formulations are designed to address specific skin concerns, such as acne or hyperpigmentation. Personalized medicine can identify genetic risk factors for skin conditions like skin cancer. Patients with a higher genetic risk may receive more frequent screenings and preventive interventions. By tailoring treatments based on an individual's genetic profile, dermatologists can minimize the risk of adverse effects and optimize treatment safety and efficacy.
Segmental Insights
Product Insights
In 2022, the Global Dysphagia Management Market largest share was held by Drug segment and is predicted to continue expanding over the coming years.
Indication Insights
In 2022, the Global Dysphagia Management Market largest share was held by Esophageal Dypshagia segment and is predicted to continue expanding over the coming years. Esophageal dysphagia is a medical condition characterized by difficulty swallowing or the sensation of food or liquids getting stuck in the chest or throat while attempting to swallow. This condition occurs when there is a problem with the esophagus, the muscular tube that connects the mouth to the stomach and plays a crucial role in the transportation of food and liquids from the mouth to the stomach. The primary symptom of esophageal dysphagia is difficulty swallowing. This can manifest as a sensation of food or liquids getting stuck or "hanging" in the chest. Other common symptoms include pain or discomfort while swallowing, regurgitation of food or liquids, and unintentional weight loss due to difficulty eating.
Distribution channels Insights
In 2022, the Global Dysphagia Management Market largest share was held by
Regional Insights
The North America region dominates the Global Dermatological Drugs Market in 2022. North America, particularly the United States, has one of the highest healthcare expenditures globally. A substantial portion of this spending goes toward pharmaceuticals, including dermatological drugs. This high level of investment in healthcare infrastructure and pharmaceuticals contributes to market dominance.
Recent Developments
- In June 2020, Adapalene gelUSP, 0.3% received FDA approval for the abbreviated new drug application(ANDA), according to Alembic Pharmaceuticals and its joint venture AleorDermaceuticals. For individuals 12 years ofage and older with acne vulgaris, adapalene gel USP, 0.3% is prescribed.
- In March 2022, The FDA hasauthorised RINVOQ (upadacitinib) for the treatment of people with moderately tohighly active ulcerative colitis (UC) who have experienced a subpar response toor intolerance to one or more tumour necrosis factor (TNF) blockers, accordingto a statement from AbbVie. With this FDA clearance, RINVOQ has been given itsfirst use in gastroenterology. Three Phase 3 randomised, double-blind,placebo-controlled clinical trials provided the effectiveness and safetyevidence supporting this FDA approval. Chronic, idiopathic,immune-mediated inflammatory bowel disease (IBD) of the large intestine knownas ulcerative colitis results in ongoing mucosal inflammation that can range insize from the rectum to the more distal colon. Rectal bleeding, stomach discomfort,bloody diarrhoea, tenesmus (a feeling of pressure), urgency, and faecalincontinence are the hallmark signs and symptoms of ulcerative colitis. Theclinical history of ulcerative colitis can range from quiescent illness tochronic refractory disease, depending on the patient. The intensity of thedisease's symptoms and its unpredictable course can place a heavy burden onpeople who are afflicted.
Key Market Players
- Eisai Co. Ltd
- Becton,Dickinson, and Company
- Hormel HealthLabs
- AstraZeneca Plc
- Cipla Ltd
- Nestle HealthScience
- Kent PrecisionFood Group Inc.
- BraccoDiagnostics Inc.
- Phagenesis Ltd
- Cook medicalInc.
| By Dermatological Diseases | By Route of Administration | By Distribution Channel | By Region | By Region |
|
|
|
|
|
Report Scope
In this report, the Global Dermatological Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below
- Dermatological Drugs Market, By Dermatological Diseases
o
o
o
o
o
- Dermatological Drugs Market, By Route of Administration
o
o
o
- Dermatological Drugs Market, By Distribution Channel
o
o
o
- Global Dermatological Drugs Market, By region
North America
Asia-Pacific
Europe
South America
Middle East & Africa
Competitive Landscape
Company Profiles
found at Customizations
Company Information
- Detailed analysis and profiling of additional market players (up to five).
Global Dermatological Drugs Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at sales@techsciresearch.com
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy